BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29

• Press Releases

  PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

  August 13, 2025

   · 

  9 min read
• Press Releases

  Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance

  August 13, 2025

   · 

  20 min read
• Press Releases

  Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy

  August 13, 2025

   · 

  8 min read
• Press Releases

  Glaukos Announces Participation in Wells Fargo Healthcare Conference 2025

  August 13, 2025

   · 

  1 min read
• Press Releases

  Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones

  August 13, 2025

   · 

  9 min read
• 

  Gene therapy

  Sarepta Provides New Elevidys Safety Data, Reveals Zero Ambulatory Deaths

  Jefferies analysts said these detailed safety outcomes confirm the gene therapy’s positive risk/benefit profile in ambulatory patients with Duchenne muscular dystrophy.

  August 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Insmed Wins Approval for First Bronchiectasis Drug and DPP1 Blocker

  Insmed’s Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the market.

  August 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Opinion

  The High Stakes Tradeoffs of a Most Favored Nation Drug Policy

  President Donald Trump loves a deal, but Most Favored Nation drug pricing isn’t a good one for anyone.

  August 13, 2025

   · 

  3 min read

   · 

  Fred Roeder
• 

  Legal

  Texas Accuses Lilly of ‘Bribing’ Prescribers To Push Mounjaro, Zepbound in New Suit

  Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.”

  August 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Generation Bio Boots 90% of Staff Amid Dwindling Cash Reserves

  The layoffs will not spare Generation’s R&D team, which will initially be retained while the biotech completes its strategic review but will eventually be let go.

  August 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac